Leishmaniases. Epidemiological Report of the Americas, December 2019
Fecha
2019Metadatos
Mostrar el registro completo del ítemResumen
[Introduction]. Since 2012, the year of the beginning of the Regional Information System for Leishmaniases in the Americas (SisLeish), countries have been making great effort to include the data within the required time, which is April 30th of the subsequent year. One of the performance indicators of the Plan of Action for Leishmaniases in the Americas 2017-2022 is the number of endemic countries that timely report the cutaneous/mucosal and visceral leishmaniasis data at the second administrative political level in SisLeish. In 2013, from the 17 countries that report data to PAHO/WHO, 29% entered the data until the scheduled date, 18% up to three months later (July 30th) and 53% six months later (October 30th).
Tabla de contenido
Introduction | Epidemiological Status: Cutaneous and mucosal leishmaniasis; Visceral Leishmaniasis | Final considerations | References
Series
Tema
Categoría del Plan Estratégico 2014-2019 de la OPS
Ítems relacionados
Mostrando ítems relacionados por Título, autor o materia.
-
Pan American Health Organization; Communicable Diseases and Environmental Determinants of Health (CDE) (PAHOUnited StatesWashington, D.C., 2013)[Presentation]. Leishmaniases are present in all continents and are endemic in 98 countries, with more than 350 million people at risk. In the Americas, leishmaniases represents a significant public health problem due to ...
-
Pan American Health Organization; Communicable Diseases and Environmental Determinants of Health (CDE) (PAHOUnited StatesWashington, D.C., 2014)[Presentation]. The strengthening health surveillance of leishmaniases in the Americas is one of the goals of the Regional Program of Leishmaniases of the Pan American Health Organization - World Health Organization ...
-
Pan American Health Organization (PAHOUnited StatesWashington, D.C., 2017)[Introduction]. In the Americas, leishmaniases remain a public health problem due to their magnitude and clinical, biological and epidemiological complexity, mainly affecting the poorest, especially in developing countries, ...